Table 6.

Primary and secondary analysis result for mild-to-moderate AD patients compared with matched non-AD controls

Primary Analysis
Output	THIN data	Projected data
	2017 (n = 33,749)*	2018 (n = 849,296)*	2019 (n = 854,374)*	2020 (n = 859,014)*	2021 (n = 863,297)*	2022 (n = 867,303)*
AD patientsa
Drug	€316,020.14	€7,952,667.93	€8,000,222.18	€8,043,669.95	€8,083,769.93	€8,121,288.35
HCRU	€11,136,681.37	€280,255,331.19	€281,931,162.78	€283,462,280.29	€284,875,420.30	€286,197,585.12
Matched non-AD controlsa
HCRU	€7,813,166.87	€196,618,866.55	€197,794,580.51	€198,868,767.36	€199,860,184.67	€200,787,776.47
Incremental costs (AD patients versus matched non-AD controls)
Incremental costs*	€3,639,534.64	€91,589,132.57	€92,136,804.44	€92,637,182.88	€93,099,005.56	€93,531,096.99

Secondary analysis**
Output	THIN data	Projected data
	2017 (n = 31,493)*	2018 (n = 793,201)*	2019 (n = 797,944)*	2020 (n = 802,278)*	2021 (n = 806,277)*	2022 (n = 810,020)*
AD patientsa
Drug	€282,272.33	€7,109,477.56	€7,151,989.82	€7,190,830.99	€7,226,679.32	€7,260,219.81
HCRU	€10,302,729.73	€259,490,629.76	€261,042,295.49	€262,459,969.32	€263,768,406.84	€264,992,609.71
Matched non-AD controlsa
HCRU	€7,307,030.84	€184,039,193.56	€185,139,685.56	€186,145,145.48	€187,073,132.23	€187,941,376.58
Incremental costs (AD patients versus matched non-AD controls)
Incremental costs	€3,277,971.08	€82,560,913.65	€83,054,599.85	€83,505,654.46	€83,921,953.87	€84,311,452.75

AD atopic dermatitis, HCRU healthcare resource utilization, THIN The Health Improvement Network

*The number of mild-to-moderate AD patients and matched non-AD controls

**Excluding AD patients treated with very potent topical corticosteroids, who most likely had at least moderate AD

^aAD patients were propensity score matched with up to three non-AD controls based on demographics including age, sex, socio-economic status and practice ID